Serum 25-hydroxyvitamin D3 and BAFF levels are associated with disease activity in primary Sjogren's syndrome

Sang Jin Lee, Hye Jin Oh, Byoong Yong Choi, Yu Jin Jang, Joo Youn Lee, Jin Kyun Park, Yeong Wook Song

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

The study investigated the association between disease activity and serum 25-hydroxyvitamin D3 (25(OH)-D3), B cell activation of the tumor necrosis factor family (BAFF), or β2 microglobulin in patients with primary Sjogren's syndrome (SS). Sixty-nine primary SS patients and 22 sicca control patients were included in the study. Disease activity was measured with EULAR Sjogren's syndrome disease activity index (ESSDAI). Serum levels of 25(OH)-D3 and β2 microglobulin were measured by radioimmunoassay and BAFF was measured by an enzyme-linked immunosorbent assay. Serum levels of 25(OH)-D3 were significantly lower in SS patients compared to the sicca controls (p=0.036). Serum levels of BAFF tended to be higher (p=0.225) and those of β2 microglobulin were significantly higher in patients with SS than in sicca controls (p=0.023). In univariate regression analyses, ESSDAI was significantly associated with serum levels of 25(OH)-D3, BAFF, and β2 microglobulin. After stepwise backward multivariate linear regression analyses including age and acute phase reactants, ESSDAI was associated with 25(OH)-D3 (β =-0.042, p=0.015) and BAFF (β = 0.001, p=0.015) in SS patients. In SS patients, ESSDAI is negatively associated with serum levels of 25(OH)-D3 and positively associated with BAFF.

Original languageEnglish
Article number5781070
JournalJournal of Immunology Research
Volume2016
DOIs
StatePublished - 2016

Fingerprint

Dive into the research topics of 'Serum 25-hydroxyvitamin D3 and BAFF levels are associated with disease activity in primary Sjogren's syndrome'. Together they form a unique fingerprint.

Cite this